Maravai Lifesciences Holdings (MRVI) Return on Capital Employed (2021 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Return on Capital Employed of 24.06% for Q1 2026, up 482.0% year-over-year from 4.13% in Q1 2025, and up 14.49% quarter-over-quarter from 28.14% in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Return on Capital Employed (2021 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 24.06% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 482.0% year-over-year to 24.06%; the TTM figure through Mar 2026 stood at 24.06% (up 482.0% YoY), while the FY2025 annual figure was 25.49%, down 571.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 24.06%, up from 28.14% in the prior quarter.
- The five-year high for Return on Capital Employed was 33.3% in Q1 2022, with the low at 37.12% in Q2 2025.
- The 5-year median for Return on Capital Employed is 3.77% (2024), against an average of 2.01%.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed jumped 1792 bps in 2022, then plunged 3313 bps in 2025.
- Maravai Lifesciences Holdings' Return on Capital Employed stood at 26.64% in 2022, then tumbled by 107 bps to 1.77% in 2023, then tumbled by 1127 bps to 21.69% in 2024, then decreased by 30 bps to 28.14% in 2025, then advanced by 14 bps to 24.06% in 2026.
- Business Quant data shows MRVI's Return on Capital Employed at 24.06% in Q1 2026, 28.14% in Q4 2025, and 23.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | -18.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.88% |
| Mar 31, 2026 | -24.06% |
| Dec 31, 2025 | -28.14% |
| Sep 30, 2025 | -23.93% |
| Jun 30, 2025 | -37.12% |
| Mar 31, 2025 | -28.88% |
| Dec 31, 2024 | -21.69% |
| Sep 30, 2024 | -15.81% |
| Jun 30, 2024 | -3.99% |
| Mar 31, 2024 | -3.77% |
| Dec 31, 2023 | -1.77% |
| Sep 30, 2023 | 3.87% |
| Jun 30, 2023 | 9.80% |
| Mar 31, 2023 | 18.83% |
| Dec 31, 2022 | 26.64% |
| Sep 30, 2022 | 29.58% |
| Jun 30, 2022 | 32.98% |
| Mar 31, 2022 | 33.30% |
| Dec 31, 2021 | 30.60% |
| Sep 30, 2021 | 26.40% |